Skip to main content

Agrylin Disease Interactions

There are 4 disease interactions with Agrylin (anagrelide).

Major

Anagrelide (applies to Agrylin) cardiac disease

Major Potential Hazard, High plausibility. Applicable conditions: Cardiovascular Disease

The use of anagrelide may produce a positive inotropic effect, vasodilation, tachycardia, palpitations, and congestive heart failure. Therapy with anagrelide should be administered cautiously in patients with cardiac disease. A cardiovascular examination is recommended prior to beginning therapy with anagrelide.

References (1)
  1. (2001) "Product Information. Agrylin (anagrelide)." Roberts Pharmaceutical Corporation
Major

Anagrelide (applies to Agrylin) liver disease

Major Potential Hazard, High plausibility.

Anagrelide undergoes extensive metabolism in the liver, with less than 1% recovered unchanged in the urine. Therapy with anagrelide should be administered cautiously in patients with liver disease (bilirubin, SGOT, or other liver measurements greater than 1.5 times normal) and only when the benefits outweigh the risks. Monitoring for signs of liver toxicity is recommended.

References (1)
  1. (2001) "Product Information. Agrylin (anagrelide)." Roberts Pharmaceutical Corporation
Major

Anagrelide (applies to Agrylin) renal dysfunction

Major Potential Hazard, Moderate plausibility.

The use of anagrelide has been rarely associated with renal failure most often in patients with serum creatinine values greater than 2.0. Therapy with anagrelide should be administered cautiously in patients with renal dysfunction. Monitoring for signs of renal toxicity is recommended in these patients.

References (1)
  1. (2001) "Product Information. Agrylin (anagrelide)." Roberts Pharmaceutical Corporation
Moderate

Anagrelide (applies to Agrylin) pulmonary dysfunction

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Pulmonary Impairment

The use of anagrelide may cause interstitial lung diseases, including allergic alveolitis, eosinophilic pneumonia, and interstitial pneumonitis. The symptoms may present as progressive dyspnea with lung infiltrations. Close monitoring should be exercised when using this agent in patients with pulmonary dysfunction. It is recommended to discontinue anagrelide and evaluate the patient if symptoms of pulmonary toxicity occur.

References (1)
  1. (2001) "Product Information. Agrylin (anagrelide)." Roberts Pharmaceutical Corporation

Switch to consumer interaction data

Agrylin drug interactions

There are 411 drug interactions with Agrylin (anagrelide).

Agrylin alcohol/food interactions

There are 2 alcohol/food interactions with Agrylin (anagrelide).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer